Ineffective Anti PD-1 Therapy After BRAF Inhibitor Failure in Advanced Melanoma

BMC Cancer - United Kingdom
doi 10.1186/s12885-018-4618-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Factors Influencing the Efficacy of Anti-Pd-1 Therapy in Chinese Patients With Advanced Melanoma

Journal of Oncology
Oncology
2019English

Oral Lichen Planus Developing After PD-1 Inhibitor Therapy in Two Patients With Malignant Melanoma

Journal of Clinical and Investigative Dermatology
2019English

Cessation of Targeted Therapy After a Complete Response in BRAF-mutant Advanced Melanoma: A Case Series

British Journal of Cancer
Cancer ResearchOncology
2016English

SCLE and Dermatomyositis in Anti‐PD‐1 Therapy

British Journal of Dermatology
DermatologyMedicine
2019English

Comment on ‘Efficacy and Toxicity of Treatment With the Anti-Ctla-4 Antibody Ipilimumab in Patients With Metastatic Melanoma After Prior Anti-Pd-1 Therapy’

British Journal of Cancer
Cancer ResearchOncology
2017English

TNFα Blockade Overcomes Resistance to Anti-Pd-1 in Experimental Melanoma

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2017English

Safety and Tumor Responses With Lambrolizumab (Anti–PD-1) in Melanoma

New England Journal of Medicine
Medicine
2013English

Systemic Therapy for Previously Untreated Advanced BRAF-mutated Melanoma: Navigating a Shifting Landscape

Immunotherapy
OncologyAllergyImmunology
2017English

2241. Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(pd-L1) Inhibitor Therapy in HIV Patients With Advanced Cancer

Open Forum Infectious Diseases
OncologyNeurology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy